Evaluation of the Stinging Potential in Human Eyes
Not Applicable
Completed
- Conditions
- Sunscreen Agents
- Interventions
- Drug: BAY 987516 (Y65-122)Drug: BAY 987516 (Y65-118)Drug: Control
- Registration Number
- NCT02872207
- Lead Sponsor
- Bayer
- Brief Summary
The objective of this study was to compare the human eye stinging potential of experimental formulas and an industry standard shampoo mixture. The study was conducted under the supervision of a Board Certified Ophthalmologist.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Male or female subjects, aged 18 to 60 years
- No medical conditions of the eyes as determined by the subjects' medical history and confirmed by ophthalmologist
- Subjects do not wear contact lenses or, if he/she does wear contact lenses, is willing to refrain from wearing these during the day of and day after the study
- Subject is willing to have the test materials instilled into the eyes and follow all protocol requirements
- Subject is willing to refrain from using false eyelashes of any type or any topical prescription, OTC or cosmetic products on their eyes, eyelids, eyelashes or the peri-orbital areas of the face on the day of the study.
- Subjects should refrain from use of make-up on testing day
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Suncare agent 1 + control BAY 987516 (Y65-122) Application of control and test product into one of the subjects two eyes. Suncare agent 1 + control Control Application of control and test product into one of the subjects two eyes. Suncare agent 2 + control BAY 987516 (Y65-118) Application of control and test product into one of the subjects two eyes. Suncare agent 2 + control Control Application of control and test product into one of the subjects two eyes.
- Primary Outcome Measures
Name Time Method Post installation discomfort upon awakening was assessed using a 5-category intensity score at 24 hours Subjective discomfort in the eye was assessed based on questions by an Ophthalmologist to the subject, and a 5-category intensity scale. up to 24 hours Tearing/Lacrimation was assessed by the Ophthalmologist using a 5-category assessment score for each of the categories up to 24 hours Objective inflammation was assessed by the Ophthalmologist using a 5-category assessment score for each of the categories at 24 hours Post installation pain/stinging was assessed using a 5-category intensity score at 24 hours Post installation itching was assessed using a 5-category intensity score at 24 hours Post installation dryness was assessed using a 5-category intensity score at 24 hours Post installation scratchiness was assessed using a 5-category intensity score at 24 hours Post installation discomfort preventing sleep was assessed using a 5-category intensity score at 24 hours Post installation excessive discharge upon awakening was assessed using a 5-category intensity score at 24 hours Post installation pain in bright sunlight was assessed using a 5-category intensity score at 24 hours
- Secondary Outcome Measures
Name Time Method Number of adverse events as a measure of safety and tolerabilitay at 24 hours